ATE198710T1 - Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa - Google Patents

Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa

Info

Publication number
ATE198710T1
ATE198710T1 AT94914087T AT94914087T ATE198710T1 AT E198710 T1 ATE198710 T1 AT E198710T1 AT 94914087 T AT94914087 T AT 94914087T AT 94914087 T AT94914087 T AT 94914087T AT E198710 T1 ATE198710 T1 AT E198710T1
Authority
AT
Austria
Prior art keywords
polypeptide
novel polypeptide
activity against
inhibiting activity
against factor
Prior art date
Application number
AT94914087T
Other languages
English (en)
Inventor
Elisha P Zeelon
Moshe M Werber
Avigdor Levanon
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Application granted granted Critical
Publication of ATE198710T1 publication Critical patent/ATE198710T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94914087T 1993-04-09 1994-04-08 Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa ATE198710T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4580593A 1993-04-09 1993-04-09
PCT/US1994/003871 WO1994023735A1 (en) 1993-04-09 1994-04-08 Novel polypeptide having factor xa inhibitory activity

Publications (1)

Publication Number Publication Date
ATE198710T1 true ATE198710T1 (de) 2001-02-15

Family

ID=21939985

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94914087T ATE198710T1 (de) 1993-04-09 1994-04-08 Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa

Country Status (14)

Country Link
EP (1) EP0696198B1 (de)
JP (1) JPH08511157A (de)
KR (1) KR960701649A (de)
AT (1) ATE198710T1 (de)
AU (1) AU682361B2 (de)
CA (1) CA2159218A1 (de)
DE (1) DE69426598T2 (de)
DK (1) DK0696198T3 (de)
ES (1) ES2155472T3 (de)
GR (1) GR3035722T3 (de)
IL (1) IL109259A0 (de)
NZ (1) NZ265507A (de)
PT (1) PT696198E (de)
WO (1) WO1994023735A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
KR20080009111A (ko) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
MX2007012548A (es) 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
KR101288027B1 (ko) 2006-04-12 2013-07-22 새비언트 파마수티컬즈 인크. 양이온 계면활성제를 이용한 단백질 정제 방법
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
US8784896B2 (en) 2012-09-17 2014-07-22 Biopep Solutions, Inc Antioxidant therapy with a whole, leech saliva extract
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) * 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
ES2052062T3 (es) * 1988-06-11 1994-07-01 Ciba Geigy Ag Nuevos polipeptidos con actividad anticoagulante.
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
IL86856A0 (en) * 1988-06-24 1988-11-30 Yissum Res Dev Co Bovine xa factor and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
EP0696198A4 (de) 1999-01-27
DE69426598T2 (de) 2001-08-09
AU6629194A (en) 1994-11-08
WO1994023735A1 (en) 1994-10-27
PT696198E (pt) 2001-07-31
AU682361B2 (en) 1997-10-02
IL109259A0 (en) 1994-07-31
HK1013315A1 (en) 1999-08-20
ES2155472T3 (es) 2001-05-16
EP0696198B1 (de) 2001-01-17
CA2159218A1 (en) 1994-10-27
EP0696198A1 (de) 1996-02-14
KR960701649A (ko) 1996-03-28
JPH08511157A (ja) 1996-11-26
GR3035722T3 (en) 2001-07-31
NZ265507A (en) 1998-09-24
DE69426598D1 (de) 2001-02-22
DK0696198T3 (da) 2001-08-06

Similar Documents

Publication Publication Date Title
DE69426598D1 (de) Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa
PL309398A1 (en) Interferon containing therapeutic composition
HU9203137D0 (en) New growth regulating proteines and epithelines rich in cysteine and their production
DE69333626D1 (de) Verwendung von Adamantan Derivaten zur Herstellung eines Medikaments zur GLAUKOMBEHANDLUNG
GB9614967D0 (en) Surface treatment process
PT86381A (en) Molecular cloning and expression of human il-3
PL307258A1 (en) Peptides capable to block calcium canals with agelenopsis aperta
DE69330272D1 (de) 4-imidomethyl-1-[2'-phenyl-2-oxoethyl]-piperidine als serotonin-5ht2-antagonisten, ihre herstellung und therapeutische anwendung
EP0460072A4 (en) Human elastase inhibitor
DE69205154D1 (de) Verwendung von mindestens einem gereinigten peptid, welches durch kaseinhydrolyse hergestellt werden kann und opiataktivität hat, als aktiven bestandteil in der herstellung einer kosmetischen zusammensetzung.
MY128309A (en) Improvements relating to termite control
DE69004794D1 (de) Verwendung eines Polypeptids mit Interleukin 2-Aktivität zur Herstellung einer zur Behandlung von einfachen Pleurageschwüren bestimmten pharmazeutischen Zusammensetzung.
CA2093819A1 (en) Platelet adhesion inhibitor
Rawczynska-Englert et al. Staphylococcal endocarditis after valve replacement(9 years of experience).
Lekan CORONA TREATMENT AS AN ADHESION PROMOTER FOR UV-/EB-CURABLE COATINGS
EP0181524A3 (de) Lymphokin
UA9891A (uk) Склоформуючий інструмент
AU3217889A (en) Production of insulin-like growth factor binding protein
Ligabue The liming intervention: Technical problems and solutions adopted.]
CA2505487A1 (en) Levobupivacaine and its use as an anaesthetic in obstetrics
GB1498740A (en) Inhibiting bacterial growth in dental appliances
UA29617A (uk) Спосіб одержання протимікробного фітозасобу з інтерфероніндукуючою активністю
CA2173207A1 (en) Levobupivacaine and its use as an anaesthetic in patients having or disposed to depressed myocardial contractility
UA7184C2 (uk) Контактний спосіб зниження артеріального тиску за методикою шпортюк м.і.
AU110262S (en) Mitten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee